Ruxolitinib treatment for polycythemia vera blood cancer: A plain language summary of the MAJIC-PV study
This Plain Language Summary of publication article (PLSP) from Future Oncology highlights the results of the MAJIC-PV study, which explored the effectiveness of ruxolitinib, a cancer drug, in treating polycythemia vera (a blood cancer causing excess red blood cell production). This condition increases blood thickness and the risk of blood clots, potentially leading to heart attacks or strokes. The study compared ruxolitinib with the best available therapy in people who had previously used the chemotherapy drug hydroxycarbamide but found it either ineffective or intolerable.
Visit the site using this link to read the article.
This PLSP is based on an article called ‘Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial’ and was published in Journal of Clinical Oncology.
Visit ASCO Publications using the link to read the original article.